Table 3.
Factors associated with the occurrence of grade III/IV toxicity.
| Characteristic | Model with cmRDI | ||
|---|---|---|---|
| Adjusted HR | 95% CI adjusted HR | p-Value | |
| Relative dose intensity | |||
| HR/10% | |||
| cmRDI of FOLFIRINOX | 1.44 | (1.21–1.72) | <0.001 |
| ECOG PS | 0.14 | ||
| 1 | 1.34 | (0.91–1.97) | |
| 0 | 1 (ref) | ||
| Center | 0.23 | ||
| Center 1 | 1 (ref) | ||
| Center 2 | 0.68 | (0.40–1.16) | |
| Center 3 | 0.71 | (0.32–1.53) | |
| Center 4 | 1.38 | (0.64–2.95) | |
| Center 5 | 1.26 | (0.75–2.11) | |
| Center 6 | 0.75 | (0.39–1.42) | |
CI, confidence interval; cmRDI, cumulative multi-drug relative dose intensity; ECOG, Eastern Cooperative Oncology Group; PS, performance status; HR, hazard ratio.